
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
        <meta name="description" content="Evidence-based clinical decision support templates for neurological diagnoses">
      
      
      
        <link rel="canonical" href="https://blondarb.github.io/neuro-plans/plans/brain-metastases/">
      
      
        <link rel="prev" href="../epidural-abscess/">
      
      
        <link rel="next" href="../elevated-icp-management/">
      
      
        
      
      
      <link rel="icon" href="../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.7.1">
    
    
      
        <title>Brain Metastases - Neuro Clinical Plans</title>
      
    
    
      <link rel="stylesheet" href="../../assets/stylesheets/main.484c7ddc.min.css">
      
        
        <link rel="stylesheet" href="../../assets/stylesheets/palette.ab4e12ef.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../assets/css/custom.css">
    
    <script>__md_scope=new URL("../..",location),__md_hash=e=>[...e].reduce(((e,_)=>(e<<5)-e+_.charCodeAt(0)),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#brain-metastases" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../.." title="Neuro Clinical Plans" class="md-header__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3zm0 5h18v2H3zm0 5h18v2H3z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Neuro Clinical Plans
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Brain Metastases
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a4 4 0 0 0-4 4 4 4 0 0 0 4 4 4 4 0 0 0 4-4 4 4 0 0 0-4-4m0 10a6 6 0 0 1-6-6 6 6 0 0 1 6-6 6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 18c-.89 0-1.74-.2-2.5-.55C11.56 16.5 13 14.42 13 12s-1.44-4.5-3.5-5.45C10.26 6.2 11.11 6 12 6a6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var palette=__md_get("__palette");if(palette&&palette.color){if("(prefers-color-scheme)"===palette.color.media){var media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']");palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent")}for(var[key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      
      
        <label class="md-header__button md-icon" for="__search">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        </label>
        <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
      
    
    
      <div class="md-header__source">
        <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    



<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../.." title="Neuro Clinical Plans" class="md-nav__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    Neuro Clinical Plans
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../.." class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Home
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../../clinical/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Interactive Clinical Tool
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--section md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3" checked>
        
          
          <label class="md-nav__link" for="__nav_3" id="__nav_3_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    Clinical Plans
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Clinical Plans
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Overview
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_2" >
        
          
          <label class="md-nav__link" for="__nav_3_2" id="__nav_3_2_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Seizures & Epilepsy
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_2">
            <span class="md-nav__icon md-icon"></span>
            
  
    Seizures & Epilepsy
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../status-epilepticus/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Status Epilepticus
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../new-onset-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    New Onset Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../breakthrough-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Breakthrough Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_3" >
        
          
          <label class="md-nav__link" for="__nav_3_3" id="__nav_3_3_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Stroke & Vascular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Stroke & Vascular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../acute-ischemic-stroke/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Ischemic Stroke
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../transient-ischemic-attack/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Transient Ischemic Attack
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../intracerebral-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Intracerebral Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../subarachnoid-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Subarachnoid Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_4" >
        
          
          <label class="md-nav__link" for="__nav_3_4" id="__nav_3_4_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuromuscular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../guillain-barre-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Guillain-Barré Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../myasthenia-gravis-crisis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenic Crisis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../myasthenia-gravis-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenia Gravis - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../neuromuscular-respiratory-failure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular Respiratory Failure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../peripheral-neuropathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Peripheral Neuropathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_5" >
        
          
          <label class="md-nav__link" for="__nav_3_5" id="__nav_3_5_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    CNS Infections
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_5_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_5">
            <span class="md-nav__icon md-icon"></span>
            
  
    CNS Infections
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../bacterial-meningitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bacterial Meningitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../hsv-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    HSV Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../autoimmune-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Autoimmune Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_6" >
        
          
          <label class="md-nav__link" for="__nav_3_6" id="__nav_3_6_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Spinal Emergencies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_6_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_6">
            <span class="md-nav__icon md-icon"></span>
            
  
    Spinal Emergencies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../acute-myelopathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Myelopathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../spinal-cord-compression-malignant/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Spinal Cord Compression (Malignant)
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../cauda-equina-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Cauda Equina Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../epidural-abscess/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Epidural Abscess
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
    
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3_7" checked>
        
          
          <label class="md-nav__link" for="__nav_3_7" id="__nav_3_7_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuro-Oncology
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_7_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_3_7">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuro-Oncology
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
        
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          
  
  
  <span class="md-ellipsis">
    
  
    Brain Metastases
  

    
  </span>
  
  

          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  
  <span class="md-ellipsis">
    
  
    Brain Metastases
  

    
  </span>
  
  

      </a>
      
        

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment-protocols" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT PROTOCOLS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendices" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDICES
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_8" >
        
          
          <label class="md-nav__link" for="__nav_3_8" id="__nav_3_8_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Critical Care
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_8_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_8">
            <span class="md-nav__icon md-icon"></span>
            
  
    Critical Care
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../elevated-icp-management/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Elevated ICP Management
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_9" >
        
          
          <label class="md-nav__link" for="__nav_3_9" id="__nav_3_9_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Demyelinating
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_9_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_9">
            <span class="md-nav__icon md-icon"></span>
            
  
    Demyelinating
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../ms-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    MS New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_10" >
        
          
          <label class="md-nav__link" for="__nav_3_10" id="__nav_3_10_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Headache
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_10_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_10">
            <span class="md-nav__icon md-icon"></span>
            
  
    Headache
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../migraine/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Migraine
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_11" >
        
          
          <label class="md-nav__link" for="__nav_3_11" id="__nav_3_11_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Movement Disorders
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_11_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_11">
            <span class="md-nav__icon md-icon"></span>
            
  
    Movement Disorders
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../parkinsons-disease-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Parkinson's Disease - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../essential-tremor/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Essential Tremor
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_12" >
        
          
          <label class="md-nav__link" for="__nav_3_12" id="__nav_3_12_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Dementia & Cognitive
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_12_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_12">
            <span class="md-nav__icon md-icon"></span>
            
  
    Dementia & Cognitive
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../dementia-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Dementia Evaluation
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../rapidly-progressive-dementia/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Rapidly Progressive Dementia
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_13" >
        
          
          <label class="md-nav__link" for="__nav_3_13" id="__nav_3_13_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Cranial Neuropathies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_13_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_13">
            <span class="md-nav__icon md-icon"></span>
            
  
    Cranial Neuropathies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../bells-palsy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bell's Palsy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_14" >
        
          
          <label class="md-nav__link" for="__nav_3_14" id="__nav_3_14_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Other
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_14_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_14">
            <span class="md-nav__icon md-icon"></span>
            
  
    Other
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../vertigo-dizziness-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Vertigo / Dizziness
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_4" >
        
          
          <label class="md-nav__link" for="__nav_4" id="__nav_4_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    References
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    References
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/lp-reference/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    LP Reference
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/tracker/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Template Tracker
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment-protocols" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT PROTOCOLS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendices" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDICES
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              
              <article class="md-content__inner md-typeset">
                
                  


  
  


<h1 id="brain-metastases">Brain Metastases<a class="headerlink" href="#brain-metastases" title="Permanent link">&para;</a></h1>
<p><strong>VERSION:</strong> 1.0
<strong>CREATED:</strong> January 27, 2026
<strong>STATUS:</strong> Initial build</p>
<hr />
<p><strong>DIAGNOSIS:</strong> Brain Metastases</p>
<p><strong>ICD-10:</strong> C79.31 (Secondary malignant neoplasm of brain), C79.32 (Secondary malignant neoplasm of cerebral meninges), C79.49 (Secondary malignant neoplasm of other parts of nervous system), G93.6 (Cerebral edema due to neoplasm)</p>
<p><strong>SYNONYMS:</strong> Brain metastases, brain mets, cerebral metastases, metastatic brain tumor, secondary brain cancer, brain tumor from cancer, metastatic disease to brain, brain lesions, CNS metastases</p>
<p><strong>SCOPE:</strong> Management of newly diagnosed or progressive brain metastases in adults. Covers initial stabilization, vasogenic edema management with corticosteroids, seizure management, imaging evaluation, molecular/histopathologic workup, treatment modalities (surgery, stereotactic radiosurgery, whole-brain radiation, systemic therapy with CNS penetration), and disposition. Excludes primary brain tumors (separate template), leptomeningeal carcinomatosis (partially addressed), and spinal metastases (separate template).</p>
<hr />
<p><strong>PRIORITY KEY:</strong> STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>
<p>═══════════════════════════════════════════════════════════════
SECTION A: ACTION ITEMS
═══════════════════════════════════════════════════════════════</p>
<h2 id="1-laboratory-workup">1. LABORATORY WORKUP<a class="headerlink" href="#1-laboratory-workup" title="Permanent link">&para;</a></h2>
<h3 id="1a-essentialcore-labs">1A. Essential/Core Labs<a class="headerlink" href="#1a-essentialcore-labs" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC with differential</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Baseline; chemotherapy planning; leukocytosis/infection; thrombocytopenia (bleeding risk, treatment candidacy)</td>
<td>WBC, platelets within normal limits; ALC (absolute lymphocyte count) for immunotherapy eligibility</td>
</tr>
<tr>
<td>CMP (BMP + LFTs)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Renal function for contrast imaging; hepatic function for chemotherapy dosing; electrolytes (SIADH from brain lesions); glucose (steroid hyperglycemia)</td>
<td>Normal; anticipate glucose elevation with dexamethasone</td>
</tr>
<tr>
<td>PT/INR, aPTT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Coagulopathy assessment; surgical candidacy; hemorrhagic metastases (melanoma, RCC, choriocarcinoma, thyroid)</td>
<td>Normal</td>
</tr>
<tr>
<td>Blood glucose</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Steroid-induced hyperglycemia; baseline before dexamethasone</td>
<td>&lt;180 mg/dL; start insulin if persistently elevated</td>
</tr>
<tr>
<td>Troponin</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Cardiac evaluation if syncope or neurogenic cardiac injury</td>
<td>Normal</td>
</tr>
<tr>
<td>Pregnancy test (β-hCG)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Treatment planning; β-hCG-secreting tumors (choriocarcinoma, germ cell); radiation contraindication in pregnancy</td>
<td>Negative; if elevated consider choriocarcinoma or germ cell tumor</td>
</tr>
<tr>
<td>LDH</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Melanoma staging; tumor burden marker; prognostic</td>
<td>Normal; elevated in melanoma, lymphoma</td>
</tr>
<tr>
<td>TSH, free T4</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Thyroid primary (thyroid cancer with brain metastases); fatigue/cognitive symptoms differential</td>
<td>Normal; abnormal may indicate thyroid primary</td>
</tr>
</tbody>
</table>
<h3 id="1b-extended-workup-second-line">1B. Extended Workup (Second-line)<a class="headerlink" href="#1b-extended-workup-second-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor markers (CEA, CA 19-9, CA 125, CA 15-3, AFP, β-hCG)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Unknown primary: CEA (lung, GI, breast), CA 19-9 (pancreatic, GI), CA 125 (ovarian), CA 15-3 (breast), AFP (hepatocellular, germ cell), β-hCG (choriocarcinoma, germ cell)</td>
<td>Elevations guide primary site evaluation</td>
</tr>
<tr>
<td>PSA (males)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Prostate cancer with brain metastases (rare but occurs)</td>
<td>Normal; elevated guides prostate workup</td>
</tr>
<tr>
<td>Serum protein electrophoresis (SPEP)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Lymphoma/myeloma differential for CNS mass lesion</td>
<td>No monoclonal protein</td>
</tr>
<tr>
<td>HIV, hepatitis B/C</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Primary CNS lymphoma (PCNSL) differential; immunosuppression assessment; treatment implications</td>
<td>Negative</td>
</tr>
<tr>
<td>ESR / CRP</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Infection differential (abscess vs. metastasis); inflammatory markers</td>
<td>Normal</td>
</tr>
<tr>
<td>Cortisol (AM)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If pituitary metastasis suspected; before initiating dexamethasone if possible</td>
<td>Normal (&gt;10 mcg/dL AM)</td>
</tr>
<tr>
<td>Prolactin</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Pituitary metastasis differential</td>
<td>Normal</td>
</tr>
</tbody>
</table>
<h3 id="1c-rarespecialized-refractory-or-atypical">1C. Rare/Specialized (Refractory or Atypical)<a class="headerlink" href="#1c-rarespecialized-refractory-or-atypical" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF cytology / flow cytometry</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Leptomeningeal carcinomatosis evaluation; diagnostic if positive (sensitivity ~50% single LP, ~80% with repeat)</td>
<td>Negative; positive = leptomeningeal disease</td>
</tr>
<tr>
<td>CSF protein, glucose, cell count</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Leptomeningeal disease (elevated protein, low glucose, lymphocytic pleocytosis)</td>
<td>Normal; elevated protein and low glucose suggest LMD</td>
</tr>
<tr>
<td>Circulating tumor DNA (ctDNA) / liquid biopsy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Unknown primary; molecular profiling when tissue biopsy not feasible; monitor treatment response</td>
<td>Detectable mutations guide therapy</td>
</tr>
<tr>
<td>Next-generation sequencing (NGS) - blood</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Identify actionable mutations (EGFR, ALK, BRAF, HER2, KRAS, ROS1) when tissue insufficient</td>
<td>Actionable driver mutations</td>
</tr>
<tr>
<td>Paraneoplastic antibody panel</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>If clinical presentation suggests paraneoplastic syndrome mimicking or coexisting with metastatic disease</td>
<td>Negative; positive changes management</td>
</tr>
<tr>
<td>Methylmalonic acid, B12, folate</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Cognitive decline differential</td>
<td>Normal</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="2-diagnostic-imaging-studies">2. DIAGNOSTIC IMAGING &amp; STUDIES<a class="headerlink" href="#2-diagnostic-imaging-studies" title="Permanent link">&para;</a></h2>
<h3 id="2a-essentialfirst-line">2A. Essential/First-line<a class="headerlink" href="#2a-essentialfirst-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT head without contrast</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Immediate in ED for acute presentation; identifies hemorrhage, mass effect, hydrocephalus</td>
<td>Mass lesion(s), hemorrhage, edema, midline shift, hydrocephalus; hemorrhagic metastases suggest melanoma, RCC, choriocarcinoma, thyroid</td>
<td>Pregnancy (benefit outweighs risk)</td>
</tr>
<tr>
<td>MRI brain with and without contrast (gadolinium)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">STAT</td>
<td>Within 24h of presentation; GOLD STANDARD for brain metastases; thin-cut (≤1mm) 3D T1 post-contrast</td>
<td>Number/size/location of metastases; ring-enhancement pattern; hemorrhagic component; leptomeningeal enhancement; dural-based vs. parenchymal</td>
<td>MRI-incompatible implants; GFR &lt;30 (gadolinium risk); severe claustrophobia</td>
</tr>
<tr>
<td>CT chest/abdomen/pelvis with contrast</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Within 24-48h if unknown primary; staging for known primary</td>
<td>Primary tumor identification; staging; additional metastatic disease</td>
<td>Contrast allergy; renal impairment</td>
</tr>
<tr>
<td>ECG (12-lead)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Baseline; pre-treatment; QTc for anti-emetics/targeted therapies</td>
<td>Normal</td>
<td>None</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Lung primary (most common source of brain metastases); pulmonary metastases; aspiration if obtunded</td>
<td>Lung mass; effusion; lymphadenopathy</td>
<td>Pregnancy (shield)</td>
</tr>
</tbody>
</table>
<h3 id="2b-extended">2B. Extended<a class="headerlink" href="#2b-extended" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>PET/CT (FDG)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Outpatient or during hospitalization; staging; unknown primary identification; ~85% sensitivity for primary site</td>
<td>Primary tumor; additional metastatic disease; lymph node involvement; treatment response assessment</td>
<td>Uncontrolled diabetes (glucose &gt;200 impairs uptake); pregnancy</td>
</tr>
<tr>
<td>CT angiography (head)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td>If hemorrhagic metastasis to evaluate vascularity; pre-surgical planning</td>
<td>Tumor vascularity; relationship to major vessels</td>
<td>Contrast allergy; renal impairment</td>
</tr>
<tr>
<td>MR spectroscopy (MRS)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Differentiating tumor from abscess or radiation necrosis; elevated choline:creatine ratio in tumor; lipid/lactate peak in necrosis</td>
<td>Elevated choline, reduced NAA in tumor; elevated lipid/lactate in necrosis</td>
<td>Same as MRI</td>
</tr>
<tr>
<td>MR perfusion (DSC or DCE)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Differentiating tumor recurrence from radiation necrosis; elevated rCBV in tumor</td>
<td>Elevated rCBV (&gt;1.5-2.0) suggests tumor; low rCBV suggests radiation necrosis</td>
<td>Same as MRI</td>
</tr>
<tr>
<td>MRI spine (whole) with contrast</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If spinal symptoms or leptomeningeal disease suspected; staging for drop metastases</td>
<td>Spinal metastases; leptomeningeal enhancement; cord compression</td>
<td>Same as MRI</td>
</tr>
<tr>
<td>Mammography / breast MRI (females)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Breast cancer is 2nd most common source of brain metastases in women</td>
<td>Breast mass or abnormality</td>
<td>Breast implants (mammography may be limited)</td>
</tr>
<tr>
<td>Stereotactic biopsy planning MRI</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If tissue diagnosis needed and surgical resection not planned; fiducial/frameless navigation sequences</td>
<td>Biopsy trajectory planning; avoidance of eloquent cortex and vasculature</td>
<td>Same as MRI</td>
</tr>
</tbody>
</table>
<h3 id="2c-rareadvanced">2C. Rare/Advanced<a class="headerlink" href="#2c-rareadvanced" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thallium SPECT or FET-PET</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Differentiating recurrent tumor vs. radiation necrosis when MR perfusion/spectroscopy equivocal</td>
<td>Increased uptake = tumor; decreased uptake = necrosis</td>
<td>Pregnancy</td>
</tr>
<tr>
<td>Functional MRI (fMRI)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Pre-surgical planning for metastases near eloquent cortex (motor, language areas)</td>
<td>Motor/language cortex mapping relative to lesion</td>
<td>Same as MRI</td>
</tr>
<tr>
<td>Diffusion tensor imaging (DTI) / Tractography</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Pre-surgical planning; white matter tract relationship to tumor</td>
<td>Tract displacement vs. infiltration</td>
<td>Same as MRI</td>
</tr>
<tr>
<td>CT-guided biopsy (extracranial)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Biopsy accessible extracranial metastatic site rather than brain (safer, easier tissue acquisition)</td>
<td>Histopathologic diagnosis; molecular profiling</td>
<td>Coagulopathy; site-specific risks</td>
</tr>
</tbody>
</table>
<h3 id="lumbar-puncture-if-indicated">Lumbar Puncture (if indicated)<a class="headerlink" href="#lumbar-puncture-if-indicated" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP with CSF cytology, flow cytometry, protein, glucose, cell count</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">URGENT</td>
<td>If leptomeningeal disease suspected (cranial neuropathies, radiculopathy, headache, altered mentation without adequate parenchymal lesion to explain); MUST ensure no obstructive hydrocephalus or significant mass effect first</td>
<td>Cytology: malignant cells (50% sensitivity single LP; repeat improves to ~80%); elevated opening pressure; elevated protein (&gt;50 mg/dL); low glucose (&lt;40 mg/dL or &lt;60% serum); lymphocytic pleocytosis</td>
<td>CONTRAINDICATED if significant mass effect, large posterior fossa lesion, obstructive hydrocephalus, midline shift &gt;5mm (herniation risk); coagulopathy; local infection at LP site</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="3-treatment-protocols">3. TREATMENT PROTOCOLS<a class="headerlink" href="#3-treatment-protocols" title="Permanent link">&para;</a></h2>
<h3 id="3a-acuteemergent-treatment">3A. Acute/Emergent Treatment<a class="headerlink" href="#3a-acuteemergent-treatment" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Protocol</th>
<th>Evidence/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dexamethasone (vasogenic edema)</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">STAT</td>
<td><strong>Symptomatic edema:</strong> 10 mg IV loading dose, then 4 mg IV/PO q6h; <strong>Moderate symptoms:</strong> 4-8 mg/day; <strong>Severe/impending herniation:</strong> 10 mg IV bolus then 4-8 mg IV q6h (up to 16-24 mg/day); Taper as soon as clinically feasible over 2-4 weeks; GI prophylaxis with PPI (omeprazole 20 mg daily) while on steroids; Monitor glucose q6h initially</td>
<td>Dexamethasone is preferred corticosteroid (minimal mineralocorticoid effect, long half-life); symptomatic improvement in 24-72h; reduces vasogenic edema via BBB stabilization; no benefit in asymptomatic patients without edema (AVOID routine prophylactic use)</td>
</tr>
<tr>
<td><strong>Seizure management (acute)</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td><strong>Active seizure:</strong> Lorazepam 0.1 mg/kg IV (max 4 mg), may repeat x1 in 5 min; <strong>Then:</strong> Levetiracetam 1000-1500 mg IV load (preferred - no drug interactions with chemotherapy) OR valproic acid 20-30 mg/kg IV load (avoid with hepatic metastases); Phenytoin/fosphenytoin only if above unavailable (interacts with many chemotherapies and targeted agents)</td>
<td>Levetiracetam preferred: no hepatic enzyme induction (does NOT reduce efficacy of steroids, chemotherapy, or targeted agents), renal elimination, broad spectrum; AAN guidelines do NOT recommend prophylactic AEDs in brain tumor patients without seizures</td>
</tr>
<tr>
<td><strong>No prophylactic anticonvulsants</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Do NOT start AEDs prophylactically in patients with brain metastases who have NOT had seizures; Applicable even peri-operatively (surgical prophylaxis may be used 7 days only per institutional protocol)</td>
<td>AAN Practice Parameter (Glantz et al., 2000; reaffirmed): No evidence supporting prophylactic AED use in brain tumor patients; side effects outweigh benefits; ASCO guideline concordant</td>
</tr>
<tr>
<td><strong>Airway/ICP management (obtunded patient)</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td><strong>GCS ≤8:</strong> Intubation; elevate HOB 30°; <strong>Acute herniation:</strong> Mannitol 1-1.5 g/kg IV bolus OR hypertonic saline (23.4% NaCl 30 mL via central line over 15 min or 3% NaCl 250 mL over 30 min); maintain PaCO2 30-35 mmHg (brief hyperventilation only as bridge to definitive treatment); Emergent neurosurgery consult for decompression</td>
<td>ICP management as bridge to definitive treatment (surgery/radiation); prolonged hyperventilation causes cerebral ischemia; osmotherapy reduces cerebral edema</td>
</tr>
<tr>
<td><strong>DVT prophylaxis</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>SCDs (sequential compression devices) immediately on admission; Pharmacologic prophylaxis: enoxaparin 40 mg SQ daily or heparin 5000 units SQ q8h - START within 24-48h unless hemorrhagic metastasis or planned surgery within 24h; Post-craniotomy: restart pharmacologic DVT ppx within 24-48h per neurosurgery guidance</td>
<td>Brain tumor patients have 20-30% VTE risk; mechanical prophylaxis alone insufficient; pharmacologic prophylaxis does NOT significantly increase intracranial hemorrhage risk (Perry et al., 2009; AVERT trial)</td>
</tr>
<tr>
<td><strong>Stress ulcer prophylaxis</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>PPI (omeprazole 20 mg daily or pantoprazole 40 mg daily) while on dexamethasone; continue throughout steroid course</td>
<td>Combined corticosteroid + critical illness increases GI bleed risk</td>
</tr>
</tbody>
</table>
<h3 id="3b-definitivetargeted-treatment">3B. Definitive/Targeted Treatment<a class="headerlink" href="#3b-definitivetargeted-treatment" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Protocol</th>
<th>Evidence/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surgical resection</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td><strong>Indications:</strong> Single (or limited ≤3) accessible metastasis; need for tissue diagnosis; symptomatic mass effect not responding to steroids; large lesion (&gt;3-4 cm) not suitable for SRS alone; good performance status (KPS ≥70); controlled systemic disease; life expectancy &gt;3 months; <strong>Post-op:</strong> MRI within 24-48h to assess residual; SRS to cavity within 2-4 weeks to reduce local recurrence (50-60% → 15-20%)</td>
<td>Patchell et al. (1990): Surgery + WBRT &gt; WBRT alone for single brain metastasis (median survival 40 vs. 15 weeks); Cavity SRS post-resection: Mahajan et al. (2017): local control improved with cavity SRS vs. observation</td>
</tr>
<tr>
<td><strong>Stereotactic radiosurgery (SRS)</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td><strong>Indications:</strong> 1-4 metastases (most centers), up to 10-15 in select cases (JLGK0901); size ≤3-4 cm; <strong>Dose:</strong> Single fraction 15-24 Gy (dose based on size: ≤2cm: 20-24 Gy, 2.1-3cm: 18 Gy, 3.1-4cm: 15 Gy) OR fractionated SRS (3-5 fractions for larger lesions or eloquent location); <strong>Timing:</strong> Within 2-4 weeks of diagnosis; Serial MRI q2-3 months post-SRS</td>
<td>Yamamoto et al. (JLGK0901): SRS alone for 2-10 metastases non-inferior to 2-4 for survival; SRS vs. WBRT: better cognitive preservation (NCCTG N0574, Brown et al., 2016); SRS + HA-WBRT vs SRS alone per NRG-CC003</td>
</tr>
<tr>
<td><strong>Whole-brain radiation therapy (WBRT)</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td><strong>Indications:</strong> &gt;10-15 metastases; leptomeningeal disease; poor surgical/SRS candidates; miliary/diffuse pattern; <strong>Standard:</strong> 30 Gy in 10 fractions (or 20 Gy in 5 fractions for poor prognosis); <strong>Hippocampal avoidance (HA-WBRT):</strong> Preferred when technically feasible (no metastases within 5mm of hippocampus): 30 Gy in 10 fractions with hippocampal sparing + memantine 20 mg daily starting with WBRT x 6 months</td>
<td>HA-WBRT + memantine (NRG-CC001, Brown et al., 2020): significantly less cognitive deterioration vs. standard WBRT + memantine at 4 and 6 months; Memantine alone (RTOG 0614): trend toward better cognitive function</td>
</tr>
<tr>
<td><strong>Systemic therapy with CNS activity</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td><strong>NSCLC with EGFR mutation:</strong> Osimertinib 80 mg daily (CNS response rate 91%); <strong>NSCLC with ALK rearrangement:</strong> Lorlatinib 100 mg daily (intracranial response 82%) or alectinib 600 mg BID (CNS response 81%); <strong>NSCLC with ROS1:</strong> Lorlatinib; <strong>Melanoma with BRAF V600:</strong> Dabrafenib + trametinib (intracranial response 58%) or encorafenib + binimetinib; <strong>Melanoma (any):</strong> Ipilimumab + nivolumab (intracranial response 46-57% in asymptomatic); <strong>HER2+ breast:</strong> Tucatinib + trastuzumab + capecitabine (HER2CLIMB: intracranial response 47%); <strong>Breast (HR+):</strong> Abemaciclib (some CNS activity); <strong>RCC:</strong> Nivolumab + ipilimumab or cabozantinib</td>
<td>CNS-penetrant systemic therapy increasingly used as upfront or adjunct to SRS; may defer radiation in asymptomatic patients with actionable mutations and small metastases; Always coordinate with medical oncology</td>
</tr>
<tr>
<td><strong>Corticosteroid taper</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Begin taper once definitive treatment initiated and symptoms improving; <strong>Taper schedule:</strong> Reduce by 2 mg every 3-5 days (from 16 mg/day: 16→12→8→6→4→2→1→off); Slower taper if symptoms recur; Monitor for adrenal insufficiency if &gt;3 weeks of steroid use</td>
<td>Prolonged steroids cause significant morbidity: hyperglycemia, myopathy (steroid myopathy can be debilitating), immunosuppression, osteoporosis, PJP risk, insomnia, psychiatric effects, GI bleeding</td>
</tr>
</tbody>
</table>
<h3 id="3c-adjunctive-treatment">3C. Adjunctive Treatment<a class="headerlink" href="#3c-adjunctive-treatment" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Protocol</th>
<th>Evidence/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Levetiracetam (post-seizure maintenance)</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>500-1500 mg PO/IV BID (start 500 mg BID, titrate to seizure control); Renal dosing if GFR &lt;50; No drug interactions with chemotherapy, targeted therapy, or steroids</td>
<td>Preferred AED in brain tumor patients due to no CYP enzyme induction; does not reduce efficacy of dexamethasone, temozolomide, or targeted agents</td>
</tr>
<tr>
<td><strong>PJP prophylaxis</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If dexamethasone &gt;20 mg/week AND concomitant temozolomide or immunosuppression: TMP-SMX 1 DS tablet 3x/week (Mon/Wed/Fri) OR atovaquone 1500 mg daily if sulfa allergic</td>
<td>Risk of Pneumocystis with prolonged corticosteroids + additional immunosuppression</td>
</tr>
<tr>
<td><strong>Glucose management (steroid-induced)</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Fingerstick glucose q6h while on dexamethasone; Sliding scale insulin initially; Basal-bolus insulin if persistently &gt;180 mg/dL; Anticipate glucose elevation typically 4-8 hours after steroid dose; May need 2-3x baseline insulin requirements</td>
<td>Dexamethasone causes significant hyperglycemia in 50-60% of patients; uncontrolled hyperglycemia worsens outcomes</td>
</tr>
<tr>
<td><strong>Calcium/Vitamin D</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Calcium 1000-1200 mg + Vitamin D 800-1000 IU daily while on prolonged steroids (&gt;2 weeks)</td>
<td>Steroid-induced osteoporosis prevention</td>
</tr>
<tr>
<td><strong>Anti-emetics (for radiation/chemotherapy)</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Ondansetron 4-8 mg IV/PO q8h PRN; Dexamethasone itself is anti-emetic; Avoid metoclopramide in brain metastases patients (extrapyramidal effects)</td>
<td>Nausea common with elevated ICP and with radiation therapy</td>
</tr>
<tr>
<td><strong>Memantine (with WBRT)</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>5 mg daily x1 week → 5 mg BID x1 week → 10 mg AM + 5 mg PM x1 week → 10 mg BID; Continue for 6 months total; Start day 1 of WBRT</td>
<td>RTOG 0614 and NRG-CC001: cognitive protection during WBRT; NMDA receptor antagonist reduces excitotoxic neuronal injury from radiation</td>
</tr>
</tbody>
</table>
<h3 id="3d-medications-to-avoid-or-use-with-caution">3D. Medications to AVOID or Use with Caution<a class="headerlink" href="#3d-medications-to-avoid-or-use-with-caution" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Medication</th>
<th>Risk/Concern</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prophylactic anticonvulsants (in patients without seizures)</td>
<td>No evidence of benefit; significant side effects (fatigue, rash, cognitive impairment); drug interactions with chemotherapy</td>
<td>Only treat seizures if they occur; levetiracetam first-line</td>
</tr>
<tr>
<td>Phenytoin / Carbamazepine / Phenobarbital (enzyme-inducing AEDs)</td>
<td>Potent CYP3A4 induction reduces efficacy of dexamethasone, many chemotherapies (temozolomide, irinotecan, paclitaxel), targeted therapies (EGFR/ALK inhibitors), and immunotherapy metabolism</td>
<td>Levetiracetam, lacosamide, brivaracetam (non-enzyme-inducing AEDs)</td>
</tr>
<tr>
<td>Bevacizumab (concurrent with surgery)</td>
<td>Impaired wound healing; hold 4-6 weeks before and 4 weeks after surgery</td>
<td>Coordinate timing with surgical and medical oncology teams</td>
</tr>
<tr>
<td>Anticoagulation (full-dose, peri-operative)</td>
<td>Increased hemorrhage risk, especially with hemorrhagic metastases (melanoma, RCC); hold for procedures</td>
<td>Mechanical prophylaxis peri-operatively; restart anticoagulation 24-48h post-procedure per neurosurgery guidance</td>
</tr>
<tr>
<td>Methotrexate (high-dose, with brain radiation)</td>
<td>Severe leukoencephalopathy when given concurrently or within weeks of cranial radiation</td>
<td>Sequence treatments; MTX before radiation if needed</td>
</tr>
<tr>
<td>Live vaccines (while on dexamethasone or chemotherapy)</td>
<td>Immunosuppression risk; disseminated infection</td>
<td>Inactivated vaccines; defer live vaccines until immune recovery</td>
</tr>
<tr>
<td>Lumbar puncture (with large posterior fossa lesion / significant mass effect)</td>
<td>Herniation risk</td>
<td>Imaging first; neurosurgery consultation; consider Ommaya reservoir for recurrent CSF sampling</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="4-other-recommendations">4. OTHER RECOMMENDATIONS<a class="headerlink" href="#4-other-recommendations" title="Permanent link">&para;</a></h2>
<h3 id="4a-essential">4A. Essential<a class="headerlink" href="#4a-essential" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurosurgery consultation</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>For surgical candidacy evaluation (single/oligometastases, mass effect, tissue diagnosis need); emergency for herniation/acute hydrocephalus</td>
</tr>
<tr>
<td>Radiation oncology consultation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>SRS vs. WBRT vs. HA-WBRT decision; coordinate with surgery (post-resection cavity SRS within 2-4 weeks)</td>
</tr>
<tr>
<td>Medical oncology consultation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Systemic therapy options; molecular profiling for targeted agents; staging; prognosis; clinical trial eligibility</td>
</tr>
<tr>
<td>Multidisciplinary tumor board</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Brain metastases management requires coordinated neurosurgery, radiation oncology, medical oncology, neuroradiology input; optimal sequencing of treatments</td>
</tr>
<tr>
<td>Goals of care discussion</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Discuss prognosis, treatment intent (curative vs. palliative), quality of life, code status; especially important for patients with limited systemic options or poor functional status (KPS &lt;50)</td>
</tr>
<tr>
<td>Pathology review with molecular profiling</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Confirm tissue diagnosis; molecular testing (NGS panel for EGFR, ALK, ROS1, BRAF, HER2, KRAS G12C, NTRK, RET, MET); PD-L1 (TPS and CPS); hormone receptors (breast); BRAF V600 (melanoma)</td>
</tr>
<tr>
<td>Fall precautions</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Brain metastases patients at high risk for falls (focal deficits, seizures, steroid myopathy, cognitive impairment); Remove fall hazards; PT/OT evaluation</td>
</tr>
<tr>
<td>Driving restrictions</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Advise against driving if seizures, visual field deficits, significant cognitive impairment, or posterior fossa lesions affecting coordination; State-specific reporting requirements</td>
</tr>
</tbody>
</table>
<h3 id="4b-extended">4B. Extended<a class="headerlink" href="#4b-extended" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palliative care consultation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Symptom management; goals of care facilitation; advance care planning; coordination of hospice if appropriate</td>
</tr>
<tr>
<td>Neuropsychology evaluation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Baseline cognitive assessment before radiation treatment; monitor cognitive decline; guide rehabilitation</td>
</tr>
<tr>
<td>Physical/occupational therapy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Functional assessment; mobility training; ADL assistance; steroid myopathy mitigation (exercise program)</td>
</tr>
<tr>
<td>Speech-language pathology</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If aphasia, dysarthria, dysphagia from metastasis location; swallow evaluation if posterior fossa lesion or obtunded</td>
</tr>
<tr>
<td>Social work / case management</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Insurance authorization for SRS/radiation; transportation; caregiver support; disability paperwork</td>
</tr>
<tr>
<td>Genetic counseling</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If young patient or cancer predisposition syndrome suspected (Li-Fraumeni, BRCA, Lynch)</td>
</tr>
<tr>
<td>Clinical trials evaluation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Active brain metastases trials (immunotherapy combinations, targeted agents, radiosensitizers); NCI clinical trials database; institutional trials</td>
</tr>
<tr>
<td>Ophthalmology consultation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If visual complaints, papilledema, metastasis near visual pathways; formal visual fields testing</td>
</tr>
</tbody>
</table>
<h3 id="4c-atypicalrefractory">4C. Atypical/Refractory<a class="headerlink" href="#4c-atypicalrefractory" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repeat biopsy / resection</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If radiation necrosis vs. recurrence unclear after advanced imaging (MR perfusion, MRS, PET); tissue diagnosis changes management</td>
</tr>
<tr>
<td>Ommaya reservoir placement</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Recurrent leptomeningeal disease requiring intrathecal chemotherapy; avoids repeated lumbar punctures</td>
</tr>
<tr>
<td>Intrathecal chemotherapy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Leptomeningeal carcinomatosis: methotrexate 12 mg IT or cytarabine (liposomal) 50 mg IT q2 weeks; via Ommaya reservoir; limited efficacy data</td>
</tr>
<tr>
<td>Laser interstitial thermal therapy (LITT)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>MRI-guided laser ablation for recurrent metastases in deep or eloquent locations; radiation necrosis treatment</td>
</tr>
<tr>
<td>Re-irradiation (SRS for recurrence)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>SRS for recurrent metastases after prior SRS or WBRT; consider cumulative dose to normal brain; risk of radiation necrosis increases</td>
</tr>
<tr>
<td>Bevacizumab for radiation necrosis</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>7.5 mg/kg IV q3 weeks for symptomatic radiation necrosis refractory to steroids; significant improvement in ~65% of patients (Levin et al., 2011)</td>
</tr>
<tr>
<td>Hospice referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Poor prognosis (DS-GPA &lt;1.0), declining functional status, exhausted treatment options, patient/family preference for comfort-focused care</td>
</tr>
</tbody>
</table>
<hr />
<p>═══════════════════════════════════════════════════════════════
SECTION B: SUPPORTING INFORMATION
═══════════════════════════════════════════════════════════════</p>
<h2 id="5-differential-diagnosis">5. DIFFERENTIAL DIAGNOSIS<a class="headerlink" href="#5-differential-diagnosis" title="Permanent link">&para;</a></h2>
<h3 id="primary-differential-diagnoses">Primary Differential Diagnoses<a class="headerlink" href="#primary-differential-diagnoses" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Key Differentiating Features</th>
<th>Distinguishing Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary brain tumor (GBM, astrocytoma)</td>
<td>Usually single; irregular enhancement; often involves corpus callosum (butterfly GBM); no known systemic cancer; infiltrative margins; surrounding FLAIR/T2 more extensive; restricted diffusion at tumor margins</td>
<td>MRI pattern; MR spectroscopy (elevated choline:creatine, reduced NAA); biopsy (IDH, MGMT, 1p19q); no systemic disease on staging CT/PET</td>
</tr>
<tr>
<td>Primary CNS lymphoma (PCNSL)</td>
<td>Periventricular location; homogeneously enhancing; restricted diffusion; may be multifocal; immunocompromised patients; responds dramatically to corticosteroids (may "disappear" = ghost tumor); typically does NOT ring-enhance unless HIV</td>
<td>MRI with diffusion restriction; AVOID steroids before biopsy if possible (may render biopsy non-diagnostic); CSF flow cytometry; vitreous biopsy if ocular involvement; HIV testing; slit lamp exam</td>
</tr>
<tr>
<td>Brain abscess</td>
<td>Ring-enhancing lesion with restricted diffusion on DWI (bright on DWI, dark on ADC in the cavity — metastases typically do NOT show central restricted diffusion); fever, elevated WBC; recent sinusitis/otitis/dental procedure/endocarditis; thin smooth enhancing rim; satellite lesions</td>
<td>DWI: central restricted diffusion is KEY distinguishing feature; MR spectroscopy: amino acid peaks (succinate, acetate, lactate); blood cultures; echocardiogram; source identification</td>
</tr>
<tr>
<td>Toxoplasmosis (immunocompromised)</td>
<td>HIV/AIDS (CD4 &lt;100); multiple ring-enhancing lesions; basal ganglia predilection; eccentric target sign; edema/mass effect</td>
<td>Toxoplasma IgG (serum); CD4 count; empiric treatment trial (response in 10-14 days supports diagnosis); if no response → biopsy; Thallium SPECT (increased uptake = lymphoma, not toxoplasmosis)</td>
</tr>
<tr>
<td>Demyelinating disease (tumefactive MS, ADEM)</td>
<td>Incomplete ring enhancement (open ring sign); younger patients; clinical dissemination in time/space; less mass effect relative to lesion size; leading edge enhancement</td>
<td>MRI: open ring enhancement, T2/FLAIR lesions in MS-typical locations; CSF: oligoclonal bands; MOG/AQP4 antibodies; clinical response to steroids</td>
</tr>
<tr>
<td>Radiation necrosis</td>
<td>History of prior brain radiation (typically 6-24 months post-treatment but can occur later); enhancing lesion at site of prior radiation; difficult to distinguish from recurrent tumor on conventional MRI</td>
<td>MR perfusion: LOW rCBV (vs. tumor with HIGH rCBV); MR spectroscopy: elevated lipid/lactate, low choline; PET: low FDG uptake (vs. tumor with high uptake); biopsy if equivocal</td>
</tr>
<tr>
<td>Neurocysticercosis</td>
<td>Travel/residence in endemic area (Latin America, sub-Saharan Africa, Southeast Asia); cystic lesions with scolex (dot within cyst); often calcified in chronic phase; seizure is common presentation</td>
<td>MRI: cystic lesion with scolex; CT: calcified granulomas; serology (cysticercosis antibodies); stool ova/parasites</td>
</tr>
<tr>
<td>Cerebral infarct (subacute)</td>
<td>Vascular territory distribution; ring enhancement at 1-4 weeks post-stroke (luxury perfusion); clinical history of acute onset; DWI abnormalities conforming to vascular territory</td>
<td>Timing of enhancement (subacute strokes enhance transiently); vascular territory distribution; DWI/ADC map evolution; clinical history of acute onset</td>
</tr>
</tbody>
</table>
<h3 id="red-flags-requiring-urgent-reassessment">Red Flags Requiring Urgent Reassessment<a class="headerlink" href="#red-flags-requiring-urgent-reassessment" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Red Flag</th>
<th>Concern</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid neurologic decline</td>
<td>Hemorrhage into metastasis; acute hydrocephalus; herniation</td>
<td>STAT CT head; neurosurgery STAT; consider intubation</td>
</tr>
<tr>
<td>New seizure (first-time)</td>
<td>Peri-tumoral irritation; hemorrhage; edema worsening; leptomeningeal spread</td>
<td>CT head (rule out hemorrhage); start AED (levetiracetam); re-image with MRI</td>
</tr>
<tr>
<td>Worst headache of life / thunderclap</td>
<td>Hemorrhagic metastasis (especially melanoma, RCC); pituitary apoplexy from pituitary metastasis</td>
<td>STAT CT head; CT angiography if SAH pattern</td>
</tr>
<tr>
<td>Fever + mental status changes</td>
<td>Brain abscess (metastasis can be misdiagnosed as abscess and vice versa); infection in immunocompromised patient; central fever from brain lesion</td>
<td>Blood cultures; CT head; LP if safe; broad-spectrum antibiotics if infection suspected</td>
</tr>
<tr>
<td>Acute vision loss</td>
<td>Pituitary metastasis with apoplexy; optic nerve/chiasm compression</td>
<td>STAT MRI; ophthalmology/neurosurgery STAT</td>
</tr>
<tr>
<td>Progressive bilateral leg weakness</td>
<td>Spinal cord compression from spinal metastases; leptomeningeal disease affecting cauda equina</td>
<td>STAT MRI whole spine; dexamethasone 10 mg IV; neurosurgery/radiation oncology STAT</td>
</tr>
<tr>
<td>Cushing syndrome features (steroid complications)</td>
<td>Prolonged dexamethasone; immunosuppression; hyperglycemia; myopathy; osteoporosis</td>
<td>Taper steroids; manage complications; alternative edema management (bevacizumab for radiation necrosis)</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="6-monitoring-parameters">6. MONITORING PARAMETERS<a class="headerlink" href="#6-monitoring-parameters" title="Permanent link">&para;</a></h2>
<h3 id="acute-phase-monitoring-first-72h">Acute Phase Monitoring (First 72h)<a class="headerlink" href="#acute-phase-monitoring-first-72h" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target</th>
<th>Action if Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurologic checks (GCS, pupil reactivity, motor exam, speech)</td>
<td>q1-2h in ICU; q2-4h on floor</td>
<td>Stable or improving exam</td>
<td>Stat CT head if decline; neurosurgery alert; consider increasing dexamethasone or osmotherapy</td>
</tr>
<tr>
<td>Blood glucose</td>
<td>q6h (q1h if insulin drip)</td>
<td>140-180 mg/dL</td>
<td>Sliding scale → basal-bolus insulin; typically requires 2-3x baseline insulin on dexamethasone</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Continuous in ICU; q4h on floor</td>
<td>SBP &lt;160 (avoid hypertensive hemorrhage into metastasis)</td>
<td>Antihypertensives PRN; avoid excessive hypotension (SBP &gt;100 to maintain cerebral perfusion)</td>
</tr>
<tr>
<td>Fluid balance / I&amp;O</td>
<td>q8h</td>
<td>Euvolemia</td>
<td>Hyponatremia common (SIADH, cerebral salt wasting); free water restriction if SIADH</td>
</tr>
<tr>
<td>Sodium</td>
<td>q6-8h initially</td>
<td>135-145 mEq/L</td>
<td>If &lt;130: fluid restrict; if &lt;125 or symptomatic: 3% NaCl; if rapidly dropping: urgent sodium correction</td>
</tr>
<tr>
<td>Seizure monitoring</td>
<td>Continuous observation; consider cEEG if altered mental status</td>
<td>No seizures; no subclinical seizures</td>
<td>AED initiation/adjustment; neurology consultation; continuous EEG monitoring</td>
</tr>
<tr>
<td>Pain assessment</td>
<td>q4h</td>
<td>NRS &lt;4/10</td>
<td>Acetaminophen 650-1000 mg q6h; dexamethasone (reduces headache from edema); opioids PRN for moderate-severe</td>
</tr>
</tbody>
</table>
<h3 id="subacuteoutpatient-monitoring">Subacute/Outpatient Monitoring<a class="headerlink" href="#subacuteoutpatient-monitoring" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target</th>
<th>Action if Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI brain with contrast</td>
<td>q2-3 months for first year post-treatment, then q3-4 months year 2, then q6 months</td>
<td>Stable/decreasing lesion size; no new metastases</td>
<td>New/progressive lesions: repeat multidisciplinary discussion; salvage SRS, surgery, systemic therapy change</td>
</tr>
<tr>
<td>Neurologic examination</td>
<td>Each clinic visit (q2-4 weeks during treatment, q1-3 months maintenance)</td>
<td>Stable or improved</td>
<td>New deficits: urgent MRI; consider tumor progression vs. radiation necrosis vs. new metastasis</td>
</tr>
<tr>
<td>KPS / ECOG performance status</td>
<td>Each visit</td>
<td>KPS ≥70 / ECOG 0-2 for active treatment</td>
<td>KPS &lt;50 / ECOG ≥3: reassess goals of care; transition to supportive/palliative care</td>
</tr>
<tr>
<td>Steroid taper progress</td>
<td>Each visit</td>
<td>Off dexamethasone or minimal dose</td>
<td>Steroid-dependent edema: consider bevacizumab, re-irradiation, or resection to enable taper</td>
</tr>
<tr>
<td>Blood glucose (while on steroids)</td>
<td>Daily fingerstick; HbA1c monthly</td>
<td>Fasting &lt;130; random &lt;180</td>
<td>Insulin titration; endocrine consultation if difficult to control</td>
</tr>
<tr>
<td>CBC (if on chemotherapy)</td>
<td>Per chemotherapy cycle protocol; typically q2-3 weeks</td>
<td>ANC &gt;1500, platelets &gt;100,000</td>
<td>Hold/dose-reduce chemotherapy; growth factor support</td>
</tr>
<tr>
<td>Hepatic/renal function</td>
<td>Monthly during systemic therapy</td>
<td>Normal</td>
<td>Dose adjustment; drug-specific monitoring per protocol</td>
</tr>
<tr>
<td>Neurocognitive screening</td>
<td>q3-6 months; MoCA or formal neuropsychological testing</td>
<td>Stable cognitive function</td>
<td>Cognitive rehabilitation; medication review; assess for depression; differentiate radiation injury vs. progression</td>
</tr>
<tr>
<td>Depression/anxiety screening (PHQ-9)</td>
<td>Each visit</td>
<td>PHQ-9 &lt;5</td>
<td>SSRI (avoid CYP interactions); psychology referral; supportive care</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="7-disposition-criteria">7. DISPOSITION CRITERIA<a class="headerlink" href="#7-disposition-criteria" title="Permanent link">&para;</a></h2>
<h3 id="admission-criteria">Admission Criteria<a class="headerlink" href="#admission-criteria" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Level of Care</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICU admission</td>
<td>GCS ≤12; signs of herniation (pupil asymmetry, posturing, Cushing triad); acute hemorrhage into metastasis with neurologic decline; post-craniotomy (first 24h); status epilepticus; respiratory compromise requiring intubation; hemodynamic instability</td>
</tr>
<tr>
<td>General neurology/neurosurgery floor</td>
<td>New diagnosis requiring workup and treatment planning; symptomatic edema requiring IV dexamethasone; post-seizure requiring monitoring and AED optimization; post-craniotomy (step-down from ICU); functional decline requiring inpatient rehabilitation planning</td>
</tr>
<tr>
<td>Observation (≤24h)</td>
<td>Known brain metastases with mild symptom change; MRI revealing progression but patient clinically stable; steroid dose adjustment with monitoring</td>
</tr>
</tbody>
</table>
<h3 id="discharge-criteria">Discharge Criteria<a class="headerlink" href="#discharge-criteria" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Criterion</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurologic stability</td>
<td>Stable or improving neurologic exam for ≥24h on current steroid dose; no new deficits</td>
</tr>
<tr>
<td>Seizure control</td>
<td>Seizure-free ≥24h on oral AED; no breakthrough seizures; AED levels therapeutic if applicable</td>
</tr>
<tr>
<td>Steroid plan</td>
<td>Oral dexamethasone regimen established with clear taper schedule; glucose management plan in place</td>
</tr>
<tr>
<td>Pain control</td>
<td>Headache adequately controlled on oral medications</td>
</tr>
<tr>
<td>Treatment plan established</td>
<td>Multidisciplinary plan documented (surgery, radiation, systemic therapy); appointments scheduled within 1-2 weeks</td>
</tr>
<tr>
<td>Functional safety</td>
<td>Safe ambulation (with or without assistive device); safe swallowing; able to perform basic ADLs or adequate caregiver support</td>
</tr>
<tr>
<td>VTE plan</td>
<td>Transition to pharmacologic prophylaxis or therapeutic anticoagulation plan if VTE occurred</td>
</tr>
<tr>
<td>Follow-up arranged</td>
<td>Neurosurgery (1-2 weeks if post-op), radiation oncology (1-2 weeks for SRS/WBRT planning), medical oncology (1-2 weeks), PCP (1 week for steroid monitoring); MRI brain scheduled at appropriate interval</td>
</tr>
<tr>
<td>Patient/family education</td>
<td>Understanding of diagnosis, treatment plan, steroid side effects, seizure precautions, when to return to ED (acute headache, new weakness, seizure, vision changes, fever)</td>
</tr>
</tbody>
</table>
<h3 id="discharge-prescriptions-checklist">Discharge Prescriptions Checklist<a class="headerlink" href="#discharge-prescriptions-checklist" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Medication</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>Taper schedule clearly documented (e.g., 4 mg q6h x 3 days → 4 mg q8h x 3 days → 4 mg q12h x 3 days → 4 mg daily x 3 days → 2 mg daily x 3 days → stop)</td>
</tr>
<tr>
<td>PPI</td>
<td>Omeprazole 20 mg daily or pantoprazole 40 mg daily while on steroids</td>
</tr>
<tr>
<td>AED (if seizure occurred)</td>
<td>Levetiracetam dose and frequency; DO NOT start if no seizure history</td>
</tr>
<tr>
<td>Insulin (if needed)</td>
<td>Sliding scale or basal-bolus regimen for steroid-induced hyperglycemia; glucometer and supplies</td>
</tr>
<tr>
<td>Calcium + Vitamin D</td>
<td>If steroids &gt;2 weeks anticipated</td>
</tr>
<tr>
<td>DVT prophylaxis (if applicable)</td>
<td>Enoxaparin transition plan if VTE occurred</td>
</tr>
<tr>
<td>Analgesics</td>
<td>Acetaminophen; limited opioid prescription if needed</td>
</tr>
<tr>
<td>TMP-SMX (if applicable)</td>
<td>If on high-dose steroids + chemotherapy (PJP prophylaxis)</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="8-evidence-references">8. EVIDENCE &amp; REFERENCES<a class="headerlink" href="#8-evidence-references" title="Permanent link">&para;</a></h2>
<h3 id="key-guidelines">Key Guidelines<a class="headerlink" href="#key-guidelines" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Guideline</th>
<th>Source</th>
<th>Year</th>
<th>Key Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management of Brain Metastases</td>
<td>Congress of Neurological Surgeons (CNS) / AANS Systematic Review</td>
<td>2019</td>
<td>Surgery for single accessible metastasis with mass effect; SRS for limited brain metastases (1-4); WBRT for multiple (&gt;10-15) or leptomeningeal disease; avoid prophylactic AEDs</td>
</tr>
<tr>
<td>Brain Metastases Molecular Testing</td>
<td>NCCN Central Nervous System Cancers</td>
<td>v1.2025</td>
<td>Comprehensive molecular profiling for actionable targets (EGFR, ALK, ROS1, BRAF, HER2, KRAS G12C, NTRK, RET, MET, PD-L1); guide systemic therapy selection</td>
</tr>
<tr>
<td>Prophylactic Anticonvulsants</td>
<td>AAN Practice Parameter (Glantz et al.)</td>
<td>2000 (reaffirmed)</td>
<td>Routine prophylactic AEDs NOT recommended in brain tumor patients without seizures</td>
</tr>
<tr>
<td>Hippocampal Avoidance WBRT</td>
<td>NRG-CC001 (Brown et al.)</td>
<td>2020</td>
<td>HA-WBRT + memantine superior to standard WBRT + memantine for cognitive preservation</td>
</tr>
<tr>
<td>SRS for Multiple Brain Metastases</td>
<td>JLGK0901 (Yamamoto et al.)</td>
<td>2014</td>
<td>SRS for 5-10 metastases non-inferior to 2-4 for overall survival</td>
</tr>
<tr>
<td>Cognitive Outcomes SRS vs. WBRT</td>
<td>NCCTG N0574 (Brown et al.)</td>
<td>2016</td>
<td>SRS alone superior to SRS + WBRT for cognitive preservation; no overall survival difference</td>
</tr>
</tbody>
</table>
<h3 id="landmark-studies">Landmark Studies<a class="headerlink" href="#landmark-studies" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Finding</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patchell et al. (1990)</td>
<td>Surgery + WBRT vs. WBRT alone for single brain metastasis: median survival 40 vs. 15 weeks; lower recurrence at original site (20% vs. 52%)</td>
<td>Established surgery as standard for single brain metastasis</td>
</tr>
<tr>
<td>Patchell et al. (1998)</td>
<td>Post-operative WBRT reduced brain recurrence (18% vs. 70%) but no survival benefit; improved neurologic death</td>
<td>Supported adjuvant radiation after surgery; now often SRS to cavity instead of WBRT</td>
</tr>
<tr>
<td>Mahajan et al. (2017) - MD Anderson</td>
<td>SRS to surgical cavity vs. observation: 12-month local recurrence 28% vs. 59% (HR 0.46)</td>
<td>Established post-operative cavity SRS as standard of care</td>
</tr>
<tr>
<td>Brown et al. (2016) - NCCTG N0574</td>
<td>SRS alone vs. SRS + WBRT: cognitive deterioration at 3 months 64% vs. 92%; no OS difference</td>
<td>Shifted practice toward SRS alone with surveillance MRI rather than WBRT</td>
</tr>
<tr>
<td>Yamamoto et al. (2014) - JLGK0901</td>
<td>SRS for 5-10 vs. 2-4 brain metastases: similar overall survival (10.8 vs. 10.8 months)</td>
<td>Expanded SRS indications to higher numbers of metastases</td>
</tr>
<tr>
<td>Brown et al. (2020) - NRG-CC001</td>
<td>HA-WBRT + memantine vs. WBRT + memantine: less cognitive deterioration at 4 months (59% vs. 68%) and 6 months; less decline in executive function and memory</td>
<td>HA-WBRT + memantine = new standard when WBRT indicated</td>
</tr>
<tr>
<td>Tawbi et al. (2018) - CheckMate 204</td>
<td>Ipilimumab + nivolumab in melanoma brain metastases: intracranial response 57% in asymptomatic patients</td>
<td>Established immunotherapy as upfront option for melanoma brain metastases</td>
</tr>
<tr>
<td>Reungwetwattana et al. (2018) - FLAURA CNS analysis</td>
<td>Osimertinib CNS response rate 91% in EGFR-mutant NSCLC with brain metastases vs. 68% standard EGFR TKI</td>
<td>Established osimertinib as preferred first-line for EGFR+ NSCLC with brain metastases</td>
</tr>
<tr>
<td>Murthy et al. (2020) - HER2CLIMB</td>
<td>Tucatinib + trastuzumab + capecitabine: intracranial response 47%; CNS-PFS 9.9 vs. 4.2 months; OS benefit in brain metastases subgroup</td>
<td>Established tucatinib combination as standard for HER2+ breast cancer brain metastases</td>
</tr>
<tr>
<td>Perry et al. (2009) - PRODIGE</td>
<td>Dalteparin vs. placebo in malignant glioma: no increase in intracranial hemorrhage with anticoagulation; VTE reduction</td>
<td>Supported pharmacologic DVT prophylaxis in brain tumor patients</td>
</tr>
<tr>
<td>Levin et al. (2011)</td>
<td>Bevacizumab for radiation necrosis: significant radiographic and clinical improvement in ~65% of patients</td>
<td>Established bevacizumab as treatment option for symptomatic radiation necrosis refractory to steroids</td>
</tr>
</tbody>
</table>
<h3 id="grading-scales">Grading Scales<a class="headerlink" href="#grading-scales" title="Permanent link">&para;</a></h3>
<p><strong>Diagnosis-Specific Graded Prognostic Assessment (DS-GPA)</strong></p>
<table>
<thead>
<tr>
<th>Component</th>
<th>Score = 0</th>
<th>Score = 0.5</th>
<th>Score = 1.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>&gt;60</td>
<td>50-60</td>
<td>&lt;50</td>
</tr>
<tr>
<td>KPS</td>
<td>&lt;70</td>
<td>70-80</td>
<td>90-100</td>
</tr>
<tr>
<td>Number of CNS metastases</td>
<td>&gt;3</td>
<td>2-3</td>
<td>1</td>
</tr>
<tr>
<td>Extracranial metastases</td>
<td>Present</td>
<td>-</td>
<td>Absent</td>
</tr>
</tbody>
</table>
<p><em>Note: DS-GPA varies by primary tumor type. The above is the general framework. Lung-molGPA incorporates molecular markers (EGFR, ALK). Melanoma-molGPA incorporates BRAF status. Breast-GPA incorporates receptor status (HR/HER2). Always use the disease-specific GPA tool.</em></p>
<table>
<thead>
<tr>
<th>DS-GPA Score (general)</th>
<th>Median Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1.0</td>
<td>2.6 months</td>
</tr>
<tr>
<td>1.5-2.0</td>
<td>4.4 months</td>
</tr>
<tr>
<td>2.5-3.0</td>
<td>9.4 months</td>
</tr>
<tr>
<td>3.5-4.0</td>
<td>14.8 months</td>
</tr>
</tbody>
</table>
<p><strong>Recursive Partitioning Analysis (RPA) Classification (RTOG)</strong></p>
<table>
<thead>
<tr>
<th>Class</th>
<th>Criteria</th>
<th>Median Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>KPS ≥70, age &lt;65, controlled primary, no extracranial metastases</td>
<td>7.1 months</td>
</tr>
<tr>
<td>Class II</td>
<td>All other patients</td>
<td>4.2 months</td>
</tr>
<tr>
<td>Class III</td>
<td>KPS &lt;70</td>
<td>2.3 months</td>
</tr>
</tbody>
</table>
<p><strong>Karnofsky Performance Status (KPS)</strong></p>
<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>Normal, no complaints</td>
</tr>
<tr>
<td>90</td>
<td>Able to carry on normal activity; minor signs/symptoms</td>
</tr>
<tr>
<td>80</td>
<td>Normal activity with effort; some signs/symptoms</td>
</tr>
<tr>
<td>70</td>
<td>Cares for self; unable to carry on normal activity or active work</td>
</tr>
<tr>
<td>60</td>
<td>Requires occasional assistance but cares for most needs</td>
</tr>
<tr>
<td>50</td>
<td>Requires considerable assistance and frequent medical care</td>
</tr>
<tr>
<td>40</td>
<td>Disabled; requires special care and assistance</td>
</tr>
<tr>
<td>30</td>
<td>Severely disabled; hospitalization indicated, death not imminent</td>
</tr>
<tr>
<td>20</td>
<td>Very sick; active supportive treatment needed</td>
</tr>
<tr>
<td>10</td>
<td>Moribund</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendices">APPENDICES<a class="headerlink" href="#appendices" title="Permanent link">&para;</a></h2>
<h3 id="appendix-a-most-common-primary-sites-of-brain-metastases">Appendix A: Most Common Primary Sites of Brain Metastases<a class="headerlink" href="#appendix-a-most-common-primary-sites-of-brain-metastases" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Primary Cancer</th>
<th>Approximate Frequency</th>
<th>Typical MRI Features</th>
<th>Key Molecular Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung (NSCLC)</td>
<td>40-50% of brain metastases</td>
<td>Multiple; any location; may hemorrhage; often ring-enhancing</td>
<td>EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET, RET, NTRK, PD-L1</td>
</tr>
<tr>
<td>Lung (SCLC)</td>
<td>10-15%</td>
<td>Multiple; tend to be small; prophylactic cranial irradiation (PCI) standard in limited-stage SCLC with response</td>
<td>PD-L1; limited targeted options</td>
</tr>
<tr>
<td>Breast</td>
<td>15-25%</td>
<td>HER2+ and triple-negative most commonly metastasize to brain; may be hemorrhagic; dural-based possible</td>
<td>HER2 (tucatinib, T-DXd), HR+ (CDK4/6 inhibitors — limited CNS data), PD-L1 (triple-negative)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>5-15%</td>
<td>Hemorrhagic (T1-hyperintense on pre-contrast MRI due to melanin and blood); multiple; any location</td>
<td>BRAF V600 (dabrafenib + trametinib), PD-1 + CTLA-4 (ipilimumab + nivolumab)</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>5-10%</td>
<td>Highly vascular; hemorrhagic; large lesions; significant surrounding edema</td>
<td>TKIs (cabozantinib), immunotherapy (ipilimumab + nivolumab)</td>
</tr>
<tr>
<td>Colorectal</td>
<td>3-5%</td>
<td>Posterior fossa predilection; typically late in disease</td>
<td>KRAS, BRAF, MSI-H/dMMR (pembrolizumab)</td>
</tr>
<tr>
<td>Unknown primary</td>
<td>5-10%</td>
<td>Variable</td>
<td>Comprehensive molecular profiling essential</td>
</tr>
</tbody>
</table>
<h3 id="appendix-b-hemorrhagic-brain-metastases-high-risk-primaries">Appendix B: Hemorrhagic Brain Metastases — High-Risk Primaries<a class="headerlink" href="#appendix-b-hemorrhagic-brain-metastases-high-risk-primaries" title="Permanent link">&para;</a></h3>
<p>Mnemonic: <strong>"MR CT"</strong> — Melanoma, Renal cell carcinoma, Choriocarcinoma, Thyroid</p>
<table>
<thead>
<tr>
<th>Primary</th>
<th>Hemorrhage Risk</th>
<th>Management Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>Very high (40-50% hemorrhagic)</td>
<td>T1 hyperintense from melanin + blood; SRS preferred over surgery when feasible (hemorrhage risk during resection); immunotherapy may be used upfront</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>High (30-40% hemorrhagic)</td>
<td>Highly vascular; pre-operative embolization considered; hemorrhage may be presenting symptom</td>
</tr>
<tr>
<td>Choriocarcinoma</td>
<td>Very high</td>
<td>β-hCG markedly elevated; chemotherapy highly effective; hemorrhage may be initial presentation</td>
</tr>
<tr>
<td>Thyroid (papillary/follicular)</td>
<td>Moderate</td>
<td>Often indolent; radioactive iodine does NOT treat brain metastases (insufficient BBB penetration); surgery or SRS needed</td>
</tr>
<tr>
<td>Lung (NSCLC on anticoagulation)</td>
<td>Moderate</td>
<td>Stop anticoagulation if hemorrhagic metastasis; reverse if on warfarin/DOACs</td>
</tr>
</tbody>
</table>
<h3 id="appendix-c-cns-penetrant-systemic-therapies-quick-reference">Appendix C: CNS-Penetrant Systemic Therapies — Quick Reference<a class="headerlink" href="#appendix-c-cns-penetrant-systemic-therapies-quick-reference" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Drug</th>
<th>CNS Response Rate</th>
<th>Key Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCLC, EGFR+</td>
<td>Osimertinib 80 mg daily</td>
<td>91%</td>
<td>FLAURA (Reungwetwattana 2018)</td>
</tr>
<tr>
<td>NSCLC, ALK+</td>
<td>Lorlatinib 100 mg daily</td>
<td>82%</td>
<td>CROWN (Shaw 2020)</td>
</tr>
<tr>
<td>NSCLC, ALK+</td>
<td>Alectinib 600 mg BID</td>
<td>81%</td>
<td>ALEX (Peters 2017)</td>
</tr>
<tr>
<td>NSCLC, ROS1+</td>
<td>Lorlatinib 100 mg daily</td>
<td>~60%</td>
<td>Phase II data</td>
</tr>
<tr>
<td>Melanoma, BRAF+</td>
<td>Dabrafenib 150 mg BID + trametinib 2 mg daily</td>
<td>58%</td>
<td>COMBI-MB (Davies 2017)</td>
</tr>
<tr>
<td>Melanoma, any</td>
<td>Ipilimumab 3 mg/kg + nivolumab 1 mg/kg</td>
<td>46-57%</td>
<td>CheckMate 204 (Tawbi 2018)</td>
</tr>
<tr>
<td>HER2+ breast</td>
<td>Tucatinib + trastuzumab + capecitabine</td>
<td>47%</td>
<td>HER2CLIMB (Murthy 2020)</td>
</tr>
<tr>
<td>HER2+ breast</td>
<td>Trastuzumab deruxtecan (T-DXd)</td>
<td>63.9%</td>
<td>DESTINY-Breast03 (Cortés 2022)</td>
</tr>
<tr>
<td>Triple-negative breast</td>
<td>Sacituzumab govitecan</td>
<td>Limited CNS data</td>
<td>ASCENT (exploratory)</td>
</tr>
<tr>
<td>RCC</td>
<td>Cabozantinib 60 mg daily</td>
<td>~55% (retrospective)</td>
<td>Retrospective series</td>
</tr>
<tr>
<td>RCC</td>
<td>Ipilimumab + nivolumab</td>
<td>~28% (brain met subgroup)</td>
<td>CheckMate 214 (subgroup)</td>
</tr>
</tbody>
</table>
<h3 id="appendix-d-treatment-algorithm-decision-framework">Appendix D: Treatment Algorithm — Decision Framework<a class="headerlink" href="#appendix-d-treatment-algorithm-decision-framework" title="Permanent link">&para;</a></h3>
<div class="highlight"><pre><span></span><code>BRAIN METASTASES DIAGNOSED
         │
         ├── Acute presentation (symptomatic edema, obtundation, herniation)?
         │         YES → Dexamethasone 10 mg IV → ICU if herniation → Emergent neurosurgery
         │         NO → Dexamethasone only if symptomatic edema present
         │
         ├── Number of metastases?
         │         │
         │         ├── 1 (single)
         │         │     ├── Surgically accessible + mass effect → Surgery → Cavity SRS
         │         │     ├── Not surgical candidate → SRS (single fraction or fractionated)
         │         │     └── With actionable mutation → Consider systemic first (e.g., osimertinib, ipi/nivo)
         │         │
         │         ├── 2-4 (oligometastases)
         │         │     ├── All ≤3-4 cm → SRS (each lesion)
         │         │     ├── 1 large + others small → Surgery for large + SRS for others
         │         │     └── With actionable mutation → Systemic + SRS
         │         │
         │         ├── 5-15
         │         │     ├── Select patients → SRS (JLGK0901 data supports up to 10-15)
         │         │     ├── Good systemic options → Systemic therapy + SRS
         │         │     └── Poor SRS candidate → HA-WBRT + memantine
         │         │
         │         └── &gt;15 or miliary/diffuse
         │               └── HA-WBRT + memantine (if hippocampus-sparing feasible)
         │                   OR standard WBRT + memantine
         │
         ├── Molecular profiling?
         │         ├── EGFR+ NSCLC → Osimertinib (may defer radiation for small, asymptomatic)
         │         ├── ALK+ NSCLC → Lorlatinib or alectinib
         │         ├── BRAF+ melanoma → Dabrafenib + trametinib ± SRS
         │         ├── Melanoma (any) → Ipilimumab + nivolumab ± SRS
         │         ├── HER2+ breast → Tucatinib combo or T-DXd ± SRS
         │         └── No actionable target → Radiation + standard systemic
         │
         └── Surveillance post-treatment
                   └── MRI brain q2-3 months year 1 → q3-4 months year 2 → q6 months ongoing
                       New/progressive lesion → Salvage SRS, surgery, or systemic change
                       Suspected radiation necrosis → Advanced imaging → Bevacizumab if confirmed
</code></pre></div>
<h3 id="appendix-e-steroid-dosing-and-taper-guide">Appendix E: Steroid Dosing and Taper Guide<a class="headerlink" href="#appendix-e-steroid-dosing-and-taper-guide" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Clinical Scenario</th>
<th>Initial Dexamethasone Dose</th>
<th>Duration Before Taper</th>
<th>Taper Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild symptoms, small edema</td>
<td>4 mg/day (2 mg BID)</td>
<td>3-5 days</td>
<td>Reduce by 1 mg every 3-5 days</td>
</tr>
<tr>
<td>Moderate symptoms</td>
<td>8-12 mg/day (4 mg q6-8h)</td>
<td>5-7 days</td>
<td>Reduce by 2 mg every 3-5 days</td>
</tr>
<tr>
<td>Severe edema / mass effect</td>
<td>16 mg/day (4 mg q6h)</td>
<td>7-14 days</td>
<td>Reduce by 2-4 mg every 3-5 days</td>
</tr>
<tr>
<td>Impending herniation</td>
<td>10 mg IV bolus → 4-8 mg q6h (up to 24 mg/day)</td>
<td>Until definitive treatment</td>
<td>Taper after surgery/radiation with clinical monitoring</td>
</tr>
<tr>
<td>Post-SRS</td>
<td>4-8 mg/day starting day of SRS</td>
<td>3-7 days</td>
<td>Rapid taper over 5-7 days if no worsening</td>
</tr>
<tr>
<td>Steroid-dependent (cannot taper)</td>
<td>Minimum effective dose</td>
<td>Ongoing</td>
<td>Consider bevacizumab, re-irradiation, or resection to enable taper</td>
</tr>
</tbody>
</table>
<p><strong>Key steroid complications to monitor:</strong> Hyperglycemia (50-60%), insomnia, myopathy (proximal weakness — may mimic disease progression), immunosuppression (PJP risk), GI bleeding, osteoporosis, psychiatric effects (mania, psychosis — usually dose-related), adrenal suppression (if &gt;3 weeks — taper slowly, do not abruptly stop).</p>
<hr />
<p><em>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</em></p>












                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
        
<div class="md-social">
  
    
    
    
    
      
      
    
    <a href="https://github.com/blondarb/neuro-plans" target="_blank" rel="noopener" title="github.com" class="md-social__link">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    
      
      
      <script id="__config" type="application/json">{"annotate": null, "base": "../..", "features": ["navigation.instant", "navigation.tracking", "navigation.sections", "navigation.expand", "navigation.top", "search.suggest", "search.highlight", "content.code.copy"], "search": "../../assets/javascripts/workers/search.2c215733.min.js", "tags": null, "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}, "version": null}</script>
    
    
      <script src="../../assets/javascripts/bundle.79ae519e.min.js"></script>
      
        <script src="../../assets/js/comments.js"></script>
      
    
  </body>
</html>